Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regenerex Pharma's Enterprise Value is $0.00 Mil.
Regenerex Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.22 Mil. Therefore, Regenerex Pharma's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Regenerex Pharma's Enterprise Value is $0.00 Mil.
Regenerex Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.18 Mil. Therefore, Regenerex Pharma's EV-to-EBITDA ratio for today is 0.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Regenerex Pharma's Enterprise Value is $0.00 Mil.
Regenerex Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Regenerex Pharma's EV-to-Revenue ratio for today is .
Regenerex Pharma Enterprise Value Historical Data
The historical data trend for Regenerex Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regenerex Pharma's Enterprise Value
For the Medical Instruments & Supplies subindustry, Regenerex Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerex Pharma's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Regenerex Pharma's Enterprise Value falls into.
Regenerex Pharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Regenerex Pharma's Enterprise Value for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerex Pharma (OTCPK:PEPT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Regenerex Pharma's current Enterprise Value is $0.00 Mil.
Regenerex Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.22 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Regenerex Pharma's current Enterprise Value is $0.00 Mil.
Regenerex Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.18 Mil.
Regenerex Pharma's current Enterprise Value is $0.00 Mil.
Regenerex Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerex Pharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Regenerex Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Regenerex Pharma (Regenerex Pharma) Business Description
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PEPT has been successfully added to your 